Company Overview and News

23
5 Reasons Why Independent Bank (INDB) Stock is a Solid Pick

2018-06-13 zacks
Independent Bank Corp. (INDB - Free Report) is a promising bet now, backed by its organic growth strategies that have placed it well for the future. Also, a strong capital and liquidity profile will support the company’s profitability. Further, analysts seem to be optimistic about its prospects as the stock is witnessing upward estimate revisions. Over the past 60 days, the Zacks Consensus Estimate for earnings has moved north by 1.
IBCP IBTX CBU XOM FCF OFG INDB

6
Turnaround And Transformational Acquisition Accelerates Growth And Drives Margins Higher For Data Communications Management

2018-06-12 seekingalpha
DCM guidance remains very achievable, supported by multiple growth efforts, the acquisition of Perennial Group and Q12018 results.
CDNTF CDNAF BCEXF KO FCF

15
Fulton Expects Q2 Results to Take a Hit of $32M, Stock Falls

2018-06-04 zacks
Shares of Fulton Financial Corporation (FULT - Free Report) declined 1.2% on last day’s trading session due to its expectations of an unfavorable impact on second-quarter 2018 results of nearly $32 million or 18 cents per share as a result of fraud committed by some employees of one of its major clients.
FULT FISI FIISO BMTC FCF FIISP

4
First Commonwealth Bank names David Folkwein as Regional President

2018-05-29 globenewswire
CINCINNATI, May 29, 2018 (GLOBE NEWSWIRE) -- First Commonwealth Bank, a wholly owned banking subsidiary of First Commonwealth Financial Corporation (NYSE:FCF), today announced the appointment of David J. Folkwein as regional president for Cincinnati effective May 29, 2018.
DCBF FCF

3
FCF / First Commonwealth Financial Corporation FORM 8-K (Current Report)

2018-05-28 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
FCF

16
5 Reasons to Add Webster Financial (WBS) in Your Portfolio

2018-05-27 zacks
Webster Financial (WBS - Free Report) seems to be a profitable pick now based on its underlying strength and earnings growth prospects. The factors that indicate upside potential in the stock include an impressive organic growth story, improving credit quality and capital strength.
DUKH FISI WBS WBSFW WBS.PRF WBS.PRE DUK FIISO FCF FIISP ICBK

3
First Commonwealth Bank Announces Closing of Subordinated Notes Offerings

2018-05-21 globenewswire
INDIANA, Pa., May 21, 2018 (GLOBE NEWSWIRE) -- First Commonwealth Bank (the "Bank"), a wholly owned subsidiary of First Commonwealth Financial Corporation (NYSE:FCF), today announced the closing of the previously announced private offering of $50 million aggregate principal amount of its 4.875% fixed-to-floating rate subordinated notes due 2028 and $50 million aggregate principal amount of its 5.50% fixed-to-floating rate subordinated notes due 2033 (collectively, the “Notes”).
FCF

3
FCF / First Commonwealth Financial Corporation FORM 8-K (Current Report)

2018-05-17 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
FCF

3
First Commonwealth Bank Announces Pricing of Subordinated Notes Offerings

2018-05-16 globenewswire
INDIANA, Pa., May 16, 2018 (GLOBE NEWSWIRE) -- First Commonwealth Bank (the "Bank"), a wholly owned subsidiary of First Commonwealth Financial Corporation (NYSE:FCF), today announced that it has priced a private offering of $50 million aggregate principal amount of its 4.875% fixed-to-floating rate subordinated notes due 2028 (the “10-Year Notes”), and $50 million aggregate principal amount of its 5.
FCF

3
FCF / First Commonwealth Financial Corporation FORM 8-K (Current Report)

2018-05-11 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
FCF

3
FCF / First Commonwealth Financial Corporation FORM 10-Q (Quarterly Report)

2018-05-09 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
FCF

3
FCF / First Commonwealth Financial Corporation FORM 8-K (Current Report)

2018-05-02 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
FCF

29
Signet Jewelers: Please, No 'Diamond-In-The-Rough' Puns

2018-05-01 seekingalpha
Signet Jewelers (NYSE:SIG) looks to be an interesting potential opportunity. Shares are trading at roughly 10x the midpoint of 2019E earnings, 6.6x ttm EBIT, and 4.91x ttm EBITDA. This is the chart over the last five years.
SIG FCF ADS SIG

3
First Commonwealth Bank: The Small Bank You've Been Looking For

2018-04-29 seekingalpha
The bank has made several acquisitions lately, and the effects of higher interest rates are showing in their net interest income.
FCF

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

Silicon Investor Message Boards

This table lists all message boards related to FCF / First Commonwealth Financial Corporation on message board site Silicon Investor.

FirstCity Liquidating Trust (FCFCL) FCFS: First Cash, Inc.
Four Crown Foods Inc. (FCFOF) FirstCity (FCFC)
FCFS First Cash Financial Services FCFOF 4CrownFoods.com
FCFN
CUSIP: 319829107